Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Meta-analysis of dolutegravir in naive, experienced and switch studies

A meta-analysis of 7340 participants in 13 randomised trials found efficacy and safety benefits for starting dolutegravir compared with other antiretrovirals in both naive and experienced participants. In the four switch studies in participants with undetectable viral load on their current ART, however, changing to dolutegravir was associated with more adverse events and discontinuations.

Published
30 April 2018
From
HIV i-Base
NHS England saved £10 million by switching to generic anti-HIV drugs in 2016

A programme to encourage clinicians to switch people to generic antiretroviral drugs saved the NHS almost £10 million in the financial year 2016-2017, Dr Laura

Published
30 April 2018
By
Roger Pebody
Switching from abacavir to TAF improves platelet function

People who switched from an antiretroviral regimen containing abacavir to one containing tenofovir alafenamide (TAF) showed less platelet reactivity, which reduces platelet aggregation or blood clotting, according to

Published
22 March 2018
By
Liz Highleyman
Failure of second-line ART is common in resource-limited countries, but modern third-line regimens work well

More than half of people in low- and middle-income countries may not maintain viral suppression on second-line antiretroviral therapy (ART), according to a study presented

Published
14 March 2018
By
Liz Highleyman
Biktarvy combo maintains viral suppression after switching therapy

People who switched to a single-tablet regimen containing the integrase inhibitor bictegravir were as likely to maintain an undetectable viral load as those who stayed on their

Published
07 March 2018
By
Liz Highleyman
Darunavir/ritonavir most durable boosted protease inhibitor in European patients, especially those switching treatment for any reason

Darunavir/ritonavir (DRV/r) is the most durable boosted protease inhibitor for antiretroviral therapy (ART)-experienced people, investigators from the EuroSIDA cohort report in HIV Medicine. People switching

Published
13 February 2018
By
Michael Carter
Boosted protease inhibitor and lamivudine provides effective maintenance treatment

HIV maintenance treatment with two drugs, a boosted protease inhibitor and lamivudine, is just as effective as three-drug treatment with a boosted protease inhibitor in people who

Published
26 October 2017
By
Keith Alcorn
HIV Regimen Switch May Contribute to Weight Gain

According to results of a study presented at IDWeek 2017, an increase in body weight is common in HIV patients who are switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to an integrase strand transfer inhibitor.

Published
09 October 2017
From
Monthly Prescribing Reference
Maraviroc matches boosted protease inhibitor treatment over 96 weeks

Treatment with maraviroc (Celsentri/Selzentry) is associated with durable HIV suppression and a favourable lipid profile, investigators report in HIV Medicine. The 96-week randomised study compared

Published
11 September 2017
By
Michael Carter
No evidence of reduced efficacy or increased side-effects when patients switch to generic drugs, comparison study finds

An analysis of 440 people switched to generic antiretroviral drugs at an Italian clinic and a matched cohort of patients who remained on their branded medication has

Published
24 August 2017
By
Roger Pebody
← First12345...28Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.